Embla Medical hfOSSFF 92 Pretax Margin % is 8.16% as of Mar. 2026, which is 31% below its 10-year median of 11.84. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $5.49. The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Embla Medical hf ranks better than 71.36% on this metric.
The historical rank and industry rank for Embla Medical hf's Pretax Margin % or its related term are showing as below:
OSSFF'
s Pretax Margin % Range Over the Past 10 Years
Min: 2.02 Med: 11.84 Max: 15.81
Current: 11.6
OSSFF's Pretax Margin % is ranked better than 71.36% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.43
vs OSSFF: 11.60
Embla Medical hf (OTCPK:OSSFF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Embla Medical hf Pretax Margin % Related Terms
Embla Medical hf Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSSFF vs ABT, SYK, MDT: Pretax Margin % Comparison
For the Medical Devices subindustry, Embla Medical hf's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embla Medical hf (OSSFF) has a Pretax Margin % of 8.16% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Embla Medical hf and its competitors. This is 31% below median its historical median of 11.84. Over the past decade, Embla Medical hf's Pretax Margin % has ranged from 2.02 to 15.81. According to the industry distribution chart, Embla Medical hf ranks #234 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 28.6%.
Is Embla Medical hf's Pretax Margin % too high?
Embla Medical hf's current Pretax Margin % of 8.16% is 31% below median its 10-year median of 11.84. Over the past 10 years, this metric has ranged from a low of 2.02 to a high of 15.81. The Medical Devices & Instruments industry median Pretax Margin % is 2.43. Embla Medical hf's value of 8.16% is 235.8% above this industry median. Based on the distribution chart, Embla Medical hf ranks #234 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's Pretax Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #234 out of 817 companies for Pretax Margin %. This puts Embla Medical hf in the upper half of its industry. The industry median Pretax Margin % is 2.43. Embla Medical hf's value of 8.16% is 235.8% above this benchmark. Historically, Embla Medical hf's own Pretax Margin % has ranged from 2.02 to 15.81 over the past decade. While the company's 10-year median is 11.84 vs. the industry median of 2.43, Embla Medical hf has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.43, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current Pretax Margin % of 8.16% is 235.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current Pretax Margin % is 8.16%, which is 31% below median its own 10-year median of 11.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current Pretax Margin % of 8.16%. The stock's GF Value™ is $5.49, compared to a current price of $4.15 — trading 24.4% below its estimated fair value. The current Pretax Margin % is 8.16%, which is 31% below median its 10-year median of 11.84 and 235.8% above the Medical Devices & Instruments industry median of 2.43. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current Pretax Margin % is 8.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 24.4% below its estimated GF Value™ of $5.49.
Key valuation signals for OSSFF:
Pretax Margin %: 8.16% (31% below median its 10-year median of 11.84)
GF Value™: $5.49 vs. price of $4.15 (24.4% below fair value)
Industry Position: 235.8% above the Medical Devices & Instruments median (#234 of 817)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OSSFF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
